Work

Real-world observational changes in biomarkers and safety profile of finerenone in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Year: 2026
Type: article
Abstract: Background Chronic kidney disease (CKD) is a major global public health challenge. Overactivation of the aldosterone-mineralocorticoid receptor axis plays a key role in renal injury. How finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, changes albuminuria, kidney function and serum potassium in non-diabetic CKD remains unclear. Methods We searched Chinese and English databases and included observational studies investigating finerenone in non-diabetic CKD. A random-effects model was used for the meta-analysis to evaluate urinary albumin-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum potassium levels, and adverse events. Results Ten studies involving 326 patients were included. UACR decreased from baseline after finerenone initiation at 1, 3, and 6 months (mean change from baseline: -62.96 mg/g, 95%CI: -115.08, -10.85, P = 0.02; -319.76 mg/g, 95%CI: -627.53, -12.00, P = 0.04; and − 322.41 mg/g, 95%CI: -539.36, -105.47, P = 0.004, respectively). eGFR decreased significantly at 3 months (mean change: -5.81 mL/min/1.73 m², P < 0.001) and stabilized at 6 months. Serum potassium levels did not change significantly at any time point, and no reported episodes of hyperkalemia requiring hospitalization were identified; however, the small sample size limits detection of rare adverse events. Statistical heterogeneity was low to moderate for UACR and eGFR (I² 0%–44%). Conclusions This meta-analysis of real-world observational evidence suggests that finerenone initiation is associated with reductions in albuminuria in the non-diabetic CKD subtypes studied. These findings describe the early trajectories of albuminuria, kidney function and serum potassium after finerenone initiation in routine practice, and should be read alongside, not as a substitute for, the randomised evidence from the FIND-CKD trial.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7235956024
FWCI:
Cites:
Cited by:
Related to: 10